Genmab A/S SEC filings GMAB

Genmab A/S has 566 filings in SEC EDGAR's recent list, going back to Apr 28, 2008. Its latest annual report, Form 20-F, was filed on Feb 17, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 5, 2026.

Genmab A/S SEC filings
Form Description Filed Period
SCHEDULE 13G Ownership over 5% (passive) Oct 5, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) May 15, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 17, 2026 —
4 Insider transaction Dec 30, 2025 Dec 26, 2025
SCHEDULE 13D/A Amended ownership over 5% (active) Dec 30, 2025 —
4 Insider transaction Dec 29, 2025 Dec 22, 2025
4 Insider transaction Dec 22, 2025 Dec 18, 2025
SCHEDULE 13D Ownership over 5% (active) Dec 19, 2025 —
4 Insider transaction Dec 18, 2025 Dec 16, 2025
3 Initial insider ownership Dec 18, 2025 Dec 12, 2025
SCHEDULE 13G Ownership over 5% (passive) Nov 14, 2025 —
144 Notice of proposed sale Jun 17, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Apr 23, 2025 —
144 Notice of proposed sale Mar 1, 2024 —
SC 13G/A Amended ownership over 5% (passive) Feb 8, 2024 —
SC 13G/A Amended ownership over 5% (passive) Feb 2, 2024 —
SC 13G Ownership over 5% (passive) Feb 6, 2023 —
SC 13G/A Amended ownership over 5% (passive) Feb 1, 2023 —
SC 13G/A Amended ownership over 5% (passive) Feb 3, 2022 —
SC 13G/A Amended ownership over 5% (passive) Jan 29, 2021 —
SC 13G Ownership over 5% (passive) Feb 7, 2020 —

Showing 22 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
GMAB (Nasdaq), GNMSF (OTC)
Headquarters
1253 Copenhagen K, Denmark
SEC filer status
Large accelerated filer
SEC CIK
1434265

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.